Drug Profile
Research programme: topoisomerase I inhibitors - Biogen
Alternative Names: HKH 40A; RTA 501; RTA 502Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer Biogen
- Class Acridines; Naphthalimides
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Sep 2023 Reata Pharmaceuticals has been acquired and merged into Biogen
- 04 Feb 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
- 06 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the Cancer pharmacodynamics section